AU2002212896A1 - N-type calcium channel antagonists for the treatment of pain - Google Patents

N-type calcium channel antagonists for the treatment of pain

Info

Publication number
AU2002212896A1
AU2002212896A1 AU2002212896A AU1289602A AU2002212896A1 AU 2002212896 A1 AU2002212896 A1 AU 2002212896A1 AU 2002212896 A AU2002212896 A AU 2002212896A AU 1289602 A AU1289602 A AU 1289602A AU 2002212896 A1 AU2002212896 A1 AU 2002212896A1
Authority
AU
Australia
Prior art keywords
pain
treatment
calcium channel
type calcium
channel antagonists
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002212896A
Other languages
English (en)
Inventor
Marc Chapdelaine
Glen Ernst
Greg Hostetler
Dannielle Kissel
John Mccauley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of AU2002212896A1 publication Critical patent/AU2002212896A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/18—Ring systems of four or more rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
AU2002212896A 2000-11-06 2001-10-31 N-type calcium channel antagonists for the treatment of pain Abandoned AU2002212896A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE0004055 2000-11-06
SE0004055A SE0004055D0 (sv) 2000-11-06 2000-11-06 N-type calcium channel antagonists for the treatment of pain
PCT/SE2001/002390 WO2002036568A1 (fr) 2000-11-06 2001-10-31 Antagonistes des canaux calciques de type n pour le traitement de la douleur

Publications (1)

Publication Number Publication Date
AU2002212896A1 true AU2002212896A1 (en) 2002-05-15

Family

ID=20281715

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002212896A Abandoned AU2002212896A1 (en) 2000-11-06 2001-10-31 N-type calcium channel antagonists for the treatment of pain

Country Status (6)

Country Link
US (1) US6906193B2 (fr)
EP (1) EP1339689A1 (fr)
JP (1) JP2004513117A (fr)
AU (1) AU2002212896A1 (fr)
SE (1) SE0004055D0 (fr)
WO (1) WO2002036568A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1541149A1 (fr) * 2002-06-26 2005-06-15 Kyowa Hakko Kogyo Co., Ltd. Inhibiteur de phosphodiesterase
ATE435214T1 (de) * 2004-09-02 2009-07-15 Vertex Pharma Als ionenkanalmodulatoren geeignete chinazoline
WO2009016812A1 (fr) * 2007-07-27 2009-02-05 Kowa Company, Ltd. Agent prophylactique et/ou thérapeutique pour l'anémie comprenant un dérivé de l'acide 2-phénylquinoléine-4-carboxylique comme principe actif

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2009155B (en) * 1977-11-07 1982-07-21 Leo Pharm Prod Ltd Chemical compounds
IT1205640B (it) * 1983-04-06 1989-03-23 Yason Srl Nuovi composti ad attivita' antiinfiammatoria,procedimento per la loro preparazione e composizioni farmaceutiche che li contengono
GB9524346D0 (en) * 1995-11-29 1996-01-31 Univ Strathclyde Polycyclic compounds
US5919776A (en) * 1996-12-20 1999-07-06 Merck & Co., Inc. Substituted aminoquinolines as modulators of chemokine receptor activity
US6576644B2 (en) * 2000-09-06 2003-06-10 Bristol-Myers Squibb Co. Quinoline inhibitors of cGMP phosphodiesterase

Also Published As

Publication number Publication date
WO2002036568A1 (fr) 2002-05-10
SE0004055D0 (sv) 2000-11-06
JP2004513117A (ja) 2004-04-30
US6906193B2 (en) 2005-06-14
US20040053964A1 (en) 2004-03-18
EP1339689A1 (fr) 2003-09-03

Similar Documents

Publication Publication Date Title
EP1425277B8 (fr) Derives de l'uree actifs comme antagonistes des recepteurs vanilloides pour le traitement de la douleur
IL196301A0 (en) Medicament for the treatment of hapatitis c
HK1051690A1 (en) Hydroxyphenyl-piperidin-4-ylidene-methyl-benzamidederivatives for the treatment of pain.
AU2002212895A1 (en) N-type calcium channel antagonists for the treatment of pain
AP2001002268A0 (en) Gardos channel antagonists
AU2001256201A1 (en) Device for administering implants
GB0213869D0 (en) The treatment of pain
IL151891A0 (en) Quinolinyl-piperidin 4-ylidene-methyl-benzamide derivatives for the treatment of pain
IL151765A0 (en) Hydroxyphenyl-piperazinyl-methyl-benzamide derivatives for the treatment of pain
AU2003237969A1 (en) Pharmaceutical composition comprising calcium channel blockers for the treatment of pain
AU2002212896A1 (en) N-type calcium channel antagonists for the treatment of pain
GB0020588D0 (en) Treatment of wounds
AU2003266960A1 (en) Composition for the treatment of pain, especially for the treatment of articular pain
AU2002326276A1 (en) N-type calcium channel antagonists for the treatment of pain
AU2002324407A1 (en) N-type calcium channel antagonists for the treatment of pain
AU2683500A (en) Compositions for the treatment of pain
AU2002315522A1 (en) Receptor agonists useful for the treatment of pain
AU2000272704A1 (en) Use of compounds for the treatment of obesity
AU2001274446A1 (en) Vip-related peptides for the treatment of skin disorders
AU2002238460A1 (en) Regulation of human calcium channel
AUPQ790900A0 (en) Treatment for scrubber effulent
AU2002327697A1 (en) Compounds for the treatment of pain
AU2002216996A1 (en) Mixture for treating skin
AU2002336574A1 (en) Methods of using 5433, a human calcium channel family member
GB9918000D0 (en) Compositions for the treatment of pain